What is Johnson & Johnson's remicade — percent change (as a percent)?

Johnson & Johnson (JNJ) reported remicade — percent change (as a percent) of -9.5% in Q1 2026.

How has Johnson & Johnson's remicade — percent change (as a percent) changed year-over-year?

Johnson & Johnson's remicade — percent change (as a percent) decreased by 226.7% year-over-year, from 7.5% to -9.5%.

What is the long-term trend for Johnson & Johnson's remicade — percent change (as a percent)?

Over 2 years (2021 to 2024), Johnson & Johnson's remicade — percent change (as a percent) has grown at a -9.5% compound annual growth rate (CAGR), from -44.1% to -36.1%.

What does remicade — percent change (as a percent) mean?

The percentage growth or decline in sales revenue for the Remicade product compared to the previous period.

Products & Services · Percent Change (as a percent)

Remicade — Percent Change (as a percent)

Johnson & Johnson Remicade — Percent Change (as a percent) decreased by 169.9% to -9.5% in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 226.7%, from 7.5% to -9.5%. Over 2 years (FY 2021 to FY 2024), Remicade — Percent Change (as a percent) shows an upward trend with a -9.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityVolatile

First reportedQ1 2018

Last reportedQ1 2026Apr 22, 2026

How to read this metric

A positive percentage indicates growth or resilience, whereas a negative percentage highlights accelerating revenue decline and the impact of market competition.

Detailed definition

This metric measures the period-over-period percentage growth or decline in net sales for the Remicade product line. It...

Peer comparison

Comparable to year-over-year or sequential growth rate metrics for individual pharmaceutical products or therapeutic franchises across the industry.

Metric ID: jnj_segment_remicade_percent_change_as_a_percent

Historical Data

18 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q1 '26
Value	-5.1%	-17.4%	-0.1%	-14.7%	-27.2%	-26.6%	-3.6%	-26.5%	-28.6%	-17.4%	-10.9%	-14.9%	-9.1%	-1.2%	7.5%	15.9%	13.6%	-9.5%
QoQ Change	—	-241.2%	+99.4%	<-999%	-85.0%	+2.2%	+86.5%	-636.1%	-7.9%	+39.2%	+37.4%	-36.7%	+38.9%	+86.8%	+725.0%	+112.0%	-14.5%	-169.9%
YoY Change	—	—	—	—	-433.3%	-52.9%	<-999%	-80.3%	-5.1%	+34.6%	+58.9%	+47.9%	+47.7%	—	+168.8%	+206.7%	+249.5%	-226.7%

Range-28.6% – 15.9%

CAGR+15.8%

Avg YoY Growth-268.0%

Median YoY Growth+34.6%

Current Streak2 quarters decline

Similar Metrics at Other Companies

Natera, Inc.NTRA View metric

ROP

Roper Technologies, Inc.ROP View metric

United TherapeuticsUTHR View metric

BiogenBIIB View metric

Gilead SciencesGILD View metric

BiogenBIIB View metric

Frequently Asked Questions

What is Johnson & Johnson's remicade — percent change (as a percent)?: Johnson & Johnson (JNJ) reported remicade — percent change (as a percent) of -9.5% in Q1 2026.
How has Johnson & Johnson's remicade — percent change (as a percent) changed year-over-year?: Johnson & Johnson's remicade — percent change (as a percent) decreased by 226.7% year-over-year, from 7.5% to -9.5%.
What is the long-term trend for Johnson & Johnson's remicade — percent change (as a percent)?: Over 2 years (2021 to 2024), Johnson & Johnson's remicade — percent change (as a percent) has grown at a -9.5% compound annual growth rate (CAGR), from -44.1% to -36.1%.
What does remicade — percent change (as a percent) mean?: The percentage growth or decline in sales revenue for the Remicade product compared to the previous period.